NO20032382L - LFA-1-antagonistforbindelser - Google Patents

LFA-1-antagonistforbindelser

Info

Publication number
NO20032382L
NO20032382L NO20032382A NO20032382A NO20032382L NO 20032382 L NO20032382 L NO 20032382L NO 20032382 A NO20032382 A NO 20032382A NO 20032382 A NO20032382 A NO 20032382A NO 20032382 L NO20032382 L NO 20032382L
Authority
NO
Norway
Prior art keywords
lfa
antagonist
Prior art date
Application number
NO20032382A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032382D0 (no
Inventor
Daniel J Burdick
Thomas Richard Gadek
Jr James C Marsters
David Oare
Mark E Reynolds
Mark S Stanley
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20032382D0 publication Critical patent/NO20032382D0/no
Publication of NO20032382L publication Critical patent/NO20032382L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
NO20032382A 2000-11-28 2003-05-27 LFA-1-antagonistforbindelser NO20032382L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25368200P 2000-11-28 2000-11-28
PCT/US2001/044203 WO2002059114A1 (en) 2000-11-28 2001-11-26 Lfa-1 antagonist compounds

Publications (2)

Publication Number Publication Date
NO20032382D0 NO20032382D0 (no) 2003-05-27
NO20032382L true NO20032382L (no) 2003-07-09

Family

ID=22961278

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032382A NO20032382L (no) 2000-11-28 2003-05-27 LFA-1-antagonistforbindelser

Country Status (17)

Country Link
US (3) US6667318B2 (de)
EP (1) EP1347968A1 (de)
JP (1) JP2004517928A (de)
KR (1) KR20030051882A (de)
CN (1) CN1592746A (de)
AU (1) AU2002248142B2 (de)
CA (1) CA2429353A1 (de)
CZ (1) CZ20031380A3 (de)
HU (1) HUP0402305A2 (de)
IL (1) IL155683A0 (de)
MX (1) MXPA03004527A (de)
NO (1) NO20032382L (de)
NZ (1) NZ525573A (de)
PL (1) PL363962A1 (de)
RU (1) RU2003114422A (de)
WO (1) WO2002059114A1 (de)
ZA (1) ZA200303357B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402305A2 (hu) * 2000-11-28 2005-02-28 Genentech, Inc. LFA-1-antagonista vegyületek, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
AU2003282510A1 (en) 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
TWI311557B (en) 2003-01-23 2009-07-01 Novartis A Pharmaceutically active diazepanes
PL1682537T3 (pl) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
US20050276803A1 (en) * 2004-04-16 2005-12-15 Genentech, Inc. Method for augmenting B cell depletion
AU2005277547B2 (en) 2004-08-16 2011-08-25 Immune Disease Institute, Inc. Method of delivering RNA interference and uses thereof
WO2006029385A2 (en) * 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
CA2609053C (en) 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
US20100008937A1 (en) * 2006-04-25 2010-01-14 Immune Disease Institute, Inc. Targeted delivery to leukocytes using non-protein carriers
WO2008089390A1 (en) * 2007-01-19 2008-07-24 Chelsea Therapeutics, Inc. New classical antifolates
EP3797775A1 (de) 2007-10-19 2021-03-31 Novartis AG Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
CA2718330A1 (en) * 2008-04-07 2009-10-15 Chelsea Therapeutics, Inc. Antifolate compositions
EP3632444A3 (de) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topische lfa-1-antagonisten zur verwendung in der lokalen behandlung von immunerkrankungen
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
CN105943534A (zh) * 2008-04-15 2016-09-21 萨可德生物科学公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化lfa−1アンタゴニスト
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2011005832A1 (en) * 2009-07-08 2011-01-13 Chelsea Therapeutics, Inc. Stable crystalline polymorphs of the dipotassium salt of (s) -2- {4- [2- (2, 4-diamin0-quinaz0lin-6-yl) -ethyl] -benzoylamino} -4-methylenξ-penta nedioic acid
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2779642A1 (en) * 2009-11-06 2011-05-12 Chelsea Therapeutics, Inc. Enzyme inhibiting compounds
WO2012064377A1 (en) * 2010-03-29 2012-05-18 Chelsea Therapeutics, Inc. Antifolate compositions
US8658652B2 (en) 2010-12-07 2014-02-25 Chelsea Therapeutics, Inc. Antifolate combinations
EP2721147B1 (de) * 2011-06-17 2018-04-25 CytoDyn, Inc. Verfahren zur behandlung retroviraler infektionen bei kleinkatzen
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
CA2944989A1 (en) 2013-04-08 2014-10-16 Cytodyn Inc. Felinized antibodies and methods of treating retroviral infections in felines
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US5424399A (en) * 1988-06-28 1995-06-13 The Children's Medical Center Corporation Human CR3α/β heterodimers
US5149780A (en) * 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
CA2090427A1 (en) * 1990-08-27 1992-02-28 Cetus Oncology Corporation Cd18 peptide medicaments for the treatment of disease
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5472973A (en) * 1991-12-12 1995-12-05 Scios Nova Inc. Fluorenyl derivatives as anti-inflammatory agents
US5470953A (en) * 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
AU6709596A (en) 1995-08-22 1997-03-19 Japan Tobacco Inc. Amide compounds and use of the same
KR100504449B1 (ko) * 1996-07-25 2005-07-29 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
HUP0101587A3 (en) 1998-03-27 2003-03-28 Genentech Inc Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
HUP0402305A2 (hu) * 2000-11-28 2005-02-28 Genentech, Inc. LFA-1-antagonista vegyületek, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Also Published As

Publication number Publication date
US6872735B2 (en) 2005-03-29
WO2002059114A1 (en) 2002-08-01
HUP0402305A2 (hu) 2005-02-28
PL363962A1 (en) 2004-11-29
KR20030051882A (ko) 2003-06-25
CN1592746A (zh) 2005-03-09
EP1347968A1 (de) 2003-10-01
MXPA03004527A (es) 2003-09-10
CA2429353A1 (en) 2002-08-01
RU2003114422A (ru) 2004-11-20
JP2004517928A (ja) 2004-06-17
NO20032382D0 (no) 2003-05-27
US20040058968A1 (en) 2004-03-25
US20050148588A1 (en) 2005-07-07
AU2002248142B8 (en) 2002-08-06
IL155683A0 (en) 2003-11-23
WO2002059114A9 (en) 2002-10-17
ZA200303357B (en) 2004-04-30
US6667318B2 (en) 2003-12-23
NZ525573A (en) 2005-08-26
CZ20031380A3 (cs) 2003-10-15
AU2002248142B2 (en) 2007-11-01
US20020119994A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
NO20032382L (no) LFA-1-antagonistforbindelser
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
NO20030276L (no) Fremgangsmåte
ATE298751T1 (de) 7-oxopyridoryrimidine
DE1274523T1 (de) Hochdruckumformspülanlage
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
IT250181Y1 (it) Custodia perfezionata per rivoltella
DE50011511D1 (de) Blowby-Heizung
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE50007634D1 (de) Kardioplegieballonkatheter
DE10052925B4 (de) Schaukelbett
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
DE10195909T1 (de) Viehfüttervorrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
ATE284887T1 (de) Thienopyrrolidinone
DE50010192D1 (de) Intaglio-druckmaschine
DE10195959T1 (de) Bohrspitzenstabilisator

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application